Drugs / NUMARZU-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05451784 | Jul 2022 → Nov 2025 overdue | triple-negative breast carcinoma | Fundacio Clinic Barcelona | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NUMARZU-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05451784 ↗ |
| Modality | Cell therapy | “The product used for treating participating patients will be selected PD1-positive TILs.” NCT05451784 ↗ |